세계의 유전성 혈관부종 시장 보고서(2025년)

Hereditary angioedema (HAE) is a rare genetic condition marked by recurrent episodes of severe swelling in the skin, gastrointestinal tract, and airways, resulting from a deficiency or dysfunction of C1 esterase inhibitor. This disorder is caused by genetic mutations affecting the complement system, leading to an overproduction of bradykinin. HAE can be life-threatening if it causes airway swelling, which requires immediate treatment with C1 inhibitor replacement or therapies targeting bradykinin.

The primary types of hereditary angioedema are type I and type II. Type I HAE, the most common form, is caused by a deficiency of C1 esterase inhibitor (C1-INH), resulting in uncontrolled bradykinin production and repeated episodes of swelling. Treatment for HAE is generally categorized into prophylactic and on-demand approaches, utilizing various drug classes such as C1 esterase inhibitors, bradykinin receptor antagonists, kallikrein inhibitors, and others. These treatments are delivered through different methods, including subcutaneous, intravenous, and oral routes, and are available via hospital pharmacies, retail pharmacies, and online pharmacies.

The hereditary angioedema market research report is one of a series of new reports from The Business Research Company that provides hereditary angioedema market statistics, including the hereditary angioedema industry global market size, regional shares, competitors with the hereditary angioedema market share, detailed hereditary angioedema market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary angioedema industry. This hereditary angioedema market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hereditary angioedema market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.84 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period can be attributed to factors such as the rising prevalence of hereditary angioedema, increased investment in research and development, a higher number of drug approvals, growing product approvals, and an increase in disposable income.

The hereditary angioedema market size is expected to see strong growth in the next few years. It will grow to $3.93 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth during the forecast period can be attributed to factors such as the increasing prevalence of rare diseases, rising medical expenditure, greater support from non-profit organizations, heightened awareness of hereditary angioedema, and a growing focus on early diagnosis. Key trends in the forecast period include technological innovations, the development of new therapies, the introduction of new drugs, advancements in diagnostic tools, and progress in genetic testing.

The increasing prevalence of rare diseases is expected to drive the growth of the hereditary angioedema (HAE) market in the coming years. Rare diseases, often referred to as orphan diseases, affect a small segment of the population, and their rising prevalence can be attributed to factors such as advancements in medical research, demographic shifts, and environmental changes. Hereditary angioedema, a notable rare disease, underscores the need for specialized treatments and awareness due to its potentially life-threatening swelling episodes. Its genetic nature and rarity make early diagnosis and targeted therapies crucial for better patient outcomes. According to Rare Disease Advisor, as of June 2022, HAE affects around 1 in 50,000 individuals, with prevalence estimates ranging from 1 in 10,000 to 1 in 150,000. In the U.S., HAE episodes account for approximately 15,000 to 30,000 emergency room visits annually. As a result, the growing number of rare disease cases is fueling the expansion of the hereditary angioedema market.

Leading companies in the hereditary angioedema market are working on developing groundbreaking products, such as oral plasma kallikrein inhibitors, to offer more convenient and effective on-demand treatment solutions for patients. These inhibitors work by blocking plasma kallikrein to prevent excessive production of bradykinin, which is central to treating hereditary angioedema. For example, in September 2024, KalVista Pharmaceuticals, Inc., a U.S.-based pharmaceutical company, announced that the FDA had accepted its new drug application (NDA) for sebetralstat, an oral plasma kallikrein inhibitor. Sebetralstat is designed for on-demand treatment of hereditary angioedema attacks in both adult and pediatric patients aged 12 and older. The NDA acceptance marks an important step towards the drug's potential approval and commercialization.

In July 2023, BioCryst Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company, partnered with Er-Kim Pharmaceuticals to commercialize ORLADEYO (berotralstat) in Turkey. This collaboration aims to improve access to ORLADEYO for hereditary angioedema patients in Turkey while expanding BioCryst's presence in the global rare disease market. Er-Kim Pharmaceuticals is a Turkish company dedicated to the development, manufacturing, and marketing of high-quality medicines across various therapeutic areas.

Major players in the hereditary angioedema market are Intellia Therapeutics Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., CSL Limited, Cipla Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Spark Therapeutics Inc., Pharming Group N.V., Pharvaris N.V., Astria Therapeutics Inc., CENTOGENE N.V., KalVista Pharmaceuticals Inc., ADARx Pharmaceuticals Inc., Adverum Biotechnologies Inc., Attune Pharmaceuticals Inc., and Lev Pharmaceuticals Inc.

North America was the largest region in the hereditary angioedema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hereditary angioedema report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hereditary angioedema market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hereditary angioedema market consists of revenues earned by entities by providing services such as diagnosis and genetic testing, acute attack management, and long-term prevention. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary angioedema market also includes sales of plasma-derived products, biologics, and therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hereditary Angioedema Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hereditary angioedema market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hereditary angioedema ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hereditary angioedema market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Hereditary Angioedema Type I; Hereditary Angioedema Type II
• 2) By Treatment Type: Prophylaxis; On-demand
• 3) By Drug Class: C-1 Esterase Inhibitors; Bradykynin Receptor Antagonist; Kallikrein Inhibitors; Other Drug Classes
• 4) By Route Of Administration: Subcutaneous; Intravenous; Oral
• 5) By Distribution channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency; Low C1-Inhibitor Levels; Reduced C1-Inhibitor Function
• 2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels; Dysfunctional C1-Inhibitor; Genetic Mutations In SERPING1 Gene
• Companies Mentioned: Intellia Therapeutics Inc.; Sanofi S.A.; Takeda Pharmaceutical Company Limited; Otsuka Pharmaceutical Co. Ltd.; CSL Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hereditary Angioedema Market Characteristics

3. Hereditary Angioedema Market Trends And Strategies

4. Hereditary Angioedema Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hereditary Angioedema Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hereditary Angioedema PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hereditary Angioedema Market Growth Rate Analysis
• 5.4. Global Hereditary Angioedema Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hereditary Angioedema Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hereditary Angioedema Total Addressable Market (TAM)

6. Hereditary Angioedema Market Segmentation

• 6.1. Global Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hereditary Angioedema Type I
• Hereditary Angioedema Type II
• 6.2. Global Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prophylaxis
• On-demand
• 6.3. Global Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• C-1 Esterase Inhibitors
• Bradykynin Receptor Antagonist
• Kallikrein Inhibitors
• Other Drug Classes
• 6.4. Global Hereditary Angioedema Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous
• Intravenous
• Oral
• 6.5. Global Hereditary Angioedema Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.6. Global Hereditary Angioedema Market, Sub-Segmentation Of Hereditary Angioedema Type I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• C1-Inhibitor Deficiency
• Low C1-Inhibitor Levels
• Reduced C1-Inhibitor Function
• 6.7. Global Hereditary Angioedema Market, Sub-Segmentation Of Hereditary Angioedema Type II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Normal C1-Inhibitor Levels
• Dysfunctional C1-Inhibitor
• Genetic Mutations In SERPING1 Gene

7. Hereditary Angioedema Market Regional And Country Analysis

• 7.1. Global Hereditary Angioedema Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hereditary Angioedema Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hereditary Angioedema Market

• 8.1. Asia-Pacific Hereditary Angioedema Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hereditary Angioedema Market

• 9.1. China Hereditary Angioedema Market Overview
• 9.2. China Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hereditary Angioedema Market

• 10.1. India Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hereditary Angioedema Market

• 11.1. Japan Hereditary Angioedema Market Overview
• 11.2. Japan Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hereditary Angioedema Market

• 12.1. Australia Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hereditary Angioedema Market

• 13.1. Indonesia Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hereditary Angioedema Market

• 14.1. South Korea Hereditary Angioedema Market Overview
• 14.2. South Korea Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hereditary Angioedema Market

• 15.1. Western Europe Hereditary Angioedema Market Overview
• 15.2. Western Europe Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hereditary Angioedema Market

• 16.1. UK Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hereditary Angioedema Market

• 17.1. Germany Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hereditary Angioedema Market

• 18.1. France Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hereditary Angioedema Market

• 19.1. Italy Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hereditary Angioedema Market

• 20.1. Spain Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hereditary Angioedema Market

• 21.1. Eastern Europe Hereditary Angioedema Market Overview
• 21.2. Eastern Europe Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hereditary Angioedema Market

• 22.1. Russia Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hereditary Angioedema Market

• 23.1. North America Hereditary Angioedema Market Overview
• 23.2. North America Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hereditary Angioedema Market

• 24.1. USA Hereditary Angioedema Market Overview
• 24.2. USA Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hereditary Angioedema Market

• 25.1. Canada Hereditary Angioedema Market Overview
• 25.2. Canada Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hereditary Angioedema Market

• 26.1. South America Hereditary Angioedema Market Overview
• 26.2. South America Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hereditary Angioedema Market

• 27.1. Brazil Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hereditary Angioedema Market

• 28.1. Middle East Hereditary Angioedema Market Overview
• 28.2. Middle East Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hereditary Angioedema Market

• 29.1. Africa Hereditary Angioedema Market Overview
• 29.2. Africa Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hereditary Angioedema Market Competitive Landscape And Company Profiles

• 30.1. Hereditary Angioedema Market Competitive Landscape
• 30.2. Hereditary Angioedema Market Company Profiles
  • 30.2.1. Intellia Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Otsuka Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. CSL Limited Overview, Products and Services, Strategy and Financial Analysis

31. Hereditary Angioedema Market Other Major And Innovative Companies

• 31.1. Cipla Limited
• 31.2. BioMarin Pharmaceutical Inc.
• 31.3. Ionis Pharmaceuticals Inc.
• 31.4. BioCryst Pharmaceuticals Inc.
• 31.5. Arrowhead Pharmaceuticals Inc.
• 31.6. Spark Therapeutics Inc.
• 31.7. Pharming Group N.V.
• 31.8. Pharvaris N.V.
• 31.9. Astria Therapeutics Inc.
• 31.10. CENTOGENE N.V.
• 31.11. KalVista Pharmaceuticals Inc.
• 31.12. ADARx Pharmaceuticals Inc.
• 31.13. Adverum Biotechnologies Inc.
• 31.14. Attune Pharmaceuticals Inc.
• 31.15. Lev Pharmaceuticals Inc

32. Global Hereditary Angioedema Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hereditary Angioedema Market

34. Recent Developments In The Hereditary Angioedema Market

35. Hereditary Angioedema Market High Potential Countries, Segments and Strategies

• 35.1 Hereditary Angioedema Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hereditary Angioedema Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hereditary Angioedema Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer